Navigation Links
Nucleix Appoints Meirav Chovav Vice President of Strategic Affairs and to the Board of Directors
Date:8/17/2009

TEL AVIV, Israel, Aug. 17 /PRNewswire/ -- Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced today that Meirav Chovav, a veteran biotechnology industry analyst and consultant, is joining the company as Vice President of Strategic Affairs. Ms. Chovav has also been elected to the company's Board of Directors.

With more than 20 years of industry and research experience, focused on in-depth coverage and analysis of the biotechnology sector, Ms. Chovav brings astute strategic and business development perspective to Nucleix. In this newly-created position, Ms. Chovav will be responsible for overseeing corporate strategy, reporting to Elon Ganor, MD, Nucleix's Chairman and Chief Executive Officer.

"We are very pleased to add Meirav to the company's management team and to the board," said Dr. Ganor. "Meirav's rich industry knowledge and strategic vision will be extraordinarily valuable as we seek to integrate Nucleix's revolutionary insights and technology in the forensic DNA testing process."

"I am very excited to join the Nucleix team, and have this unique opportunity to resume my work in the industry as an active participant in an emerging company," said Ms. Chovav. "Nucleix's focus, breakthrough research and technology and remarkable accomplishments are very impressive. In many ways, Nucleix is reminiscent of some of the outstanding opportunities that I have had the good fortune to be associated with during my Wall Street career."

Ms. Chovav holds an MBA from Rensselaer Polytechnic Institute and an MS in molecular biology from the University of Rochester. A well-respected biotechnology research analyst, Ms. Chovav is renowned for her original coverage of large cap biotechnology companies such as AMGEN, Genentech and Biogen, in addition to many other leading life sciences companies. From 1993-2004, Ms. Chovav led coverage of the biotechnology/life science sector as a Wall Street equity research analyst, serving as a senior biotechnology analyst/Managing Director of the health care groups at UBS, Credit Suisse First Boston and Salomon Smith Barney (Citigroup). For ten consecutive years (1994-2003), until she left the equity research field, she was ranked on the Institutional Investor "All-America Research Team" in the biotechnology sector. Ms. Chovav has also been recognized by The Wall Street Journal as the best stock picker in the biotechnology sector in the "Best on the Street" survey and by Bloomberg.

About Nucleix

Nucleix, an emerging life science company specializing in forensic DNA analysis, has developed a "DNA authentication" assay for forensic casework samples with potential applications across multiple DNA analysis and validation fields. DNA fingerprinting has been established as one of the most important forensic tools in criminal investigations. Nucleix scientists have demonstrated the viability of creating artificial DNA and "biological identify theft.(1)" Using basic equipment and know-how, DNA with any desired profile can be fabricated in the lab, and this artificial DNA can then be planted in crime scenes as fake evidence. Until recently, there has been no way to distinguish between genetic profiles obtained from falsified DNA samples, which can appear identical to real biological profiles based on current analytical protocols and technologies. Nucleix's proprietary assays can distinguish between "fake" (in-vitro synthesized) DNA, and "real" (in-vivo generated) DNA. The company is committed to developing state-of-the-art "DNA authentication" assays that can be integrated into the standard forensic procedure, in order to maintain the high credibility of DNA evidence in the courtroom and other uses. For additional information on Nucleix, please visit the company's website athttp://www.nucleix.com.

1 D. Frumkin, et al., Authentication of forensic DNA samples, Forensic Sci. Int. Genet. (2009), doi:10.1016/j.fsigen.2009.06.009


'/>"/>
SOURCE Nucleix, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral appoints new board member
2. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
3. China Sky One Medical, Inc. Appoints New Independent Director
4. Omeros Appoints New Vice President of Clinical Development
5. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
6. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
7. Brookstone Pharmaceuticals Appoints New Corporate Position
8. PDI Appoints Gerald P. Belle as Lead Independent Director
9. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
10. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
11. Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/21/2016)... 2016 Unique technology combines ... superior security   Xura, Inc. ... secure digital communications services, today announced it is working ... enterprise customers, particularly those in the Financial Services Sector, ... authentication within a mobile app, alongside, and in combination ...
Breaking Biology News(10 mins):